12 results on '"Studnicka, Michael"'
Search Results
2. Restricted spirometry and cardiometabolic comorbidities: results from the international population based BOLD study
- Author
-
Kulbacka-Ortiz, Katarzyna, Triest, Filip J. J., Franssen, Frits M. E., Wouters, Emiel F. M., Studnicka, Michael, Vollmer, William M., Lamprecht, Bernd, Burney, Peter G. J., Amaral, Andre F. S., and Vanfleteren, Lowie E. G. W.
- Published
- 2022
- Full Text
- View/download PDF
3. Comorbidity burden and survival in patients with idiopathic pulmonary fibrosis: the EMPIRE registry study
- Author
-
Jovanovic, Dragana M., Šterclová, Martina, Mogulkoc, Nesrin, Lewandowska, Katarzyna, Müller, Veronika, Hájková, Marta, Studnicka, Michael, Tekavec-Trkanjec, Jasna, Littnerová, Simona, and Vašáková, Martina
- Published
- 2022
- Full Text
- View/download PDF
4. Health-related quality of life associates with change in FEV1 in COPD: results from the COSYCONET cohort.
- Author
-
Lutter, Johanna I., Jörres, Rudolf A., Kahnert, Kathrin, Schwarzkopf, Larissa, Studnicka, Michael, Karrasch, Stefan, Schulz, Holger, Vogelmeier, Claus F., Holle, Rolf, for the COSYCONET Study Group, Andreas, Stefan, Bals, Robert, Behr, Jürgen, Bewig, Burkhard, Buhl, Roland, Ewert, Ralf, Stubbe, Beate, Ficker, Joachim H., Gogol, Manfred, and Grohé, Christian
- Subjects
OBSTRUCTIVE lung diseases ,QUALITY of life ,VISUAL analog scale - Abstract
Background: Forced expiratory volume in one second (FEV1) characterizes the pathophysiology of COPD and different trajectories of FEV1 decline have been observed in patients with COPD (e.g. gradual or episodic). There is limited information about the development of patient-reported health-related quality of life (HRQL) over the full range of the natural history of COPD. We examined the longitudinal association between change in FEV1 and change in disease-specific and generic HRQL.Methods: We analysed data of 1734 patients with COPD participating in the COSYCONET cohort with up to 3 years of follow-up. Patients completed the Saint George's Respiratory Questionnaire (SGRQ) and the EQ-5D Visual Analog Scale (EQ VAS). Change score models were used to investigate the relationship between HRQL and FEV1 and to calculate mean changes in HRQL per FEV1 change categories [decrease (≤ - 100 ml), no change, increase (≥ 100 ml)] after 3 years. Applying hierarchical linear models (HLM), we estimated the cross-sectional between-subject difference and the longitudinal within-subject change of HRQL as related to a FEV1 difference or change.Results: We observed a statistically significant deterioration in SGRQ (total score + 1.3 units) after 3 years, which was completely driven by the activity component (+ 4 units). No significant change was found for the generic EQ VAS. Over the same period, 58% of patients experienced a decrease in FEV1, 28% were recorded as no change in FEV1, and 13% experienced an increase. The relationship between HRQL and FEV1 was found to be approximately linear with decrease in FEV1 being statistically significantly associated with a deterioration in SGRQ (+ 3.20 units). Increase in FEV1 was associated with improvements in SGRQ (- 3.81 units). The associations between change in FEV1 and the EQ VAS were similar. Results of the HLMs were consistent and highly statistically significant, indicating cross-sectional and longitudinal associations. The largest estimates were found for the association between FEV1 and the SGRQ activity domain.Conclusions: Difference and change in FEV1 over time correlate with difference and change in disease-specific and generic HRQL. We conclude, that deterioration of HRQL should induce timely re-examination of physical status and lung function and possibly reassessment of therapeutic regimes.Trial Registration: NCT01245933. Date of registration: 18 November 2010. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
5. The European MultiPartner IPF registry (EMPIRE): validating long-term prognostic factors in idiopathic pulmonary fibrosis.
- Author
-
Tran, Tanja, Šterclová, Martina, Mogulkoc, Nesrin, Lewandowska, Katarzyna, Müller, Veronika, Hájková, Marta, Kramer, Mordechai R., Jovanović, Dragana, Tekavec-Trkanjec, Jasna, Studnicka, Michael, Stoeva, Natalia, Hejduk, Karel, Dušek, Ladislav, Suissa, Samy, Vašáková, Martina, for the EMPIRE registry, Zolnowska, Beata, Bartoš, Vladimír, Králové, Hradec, and Slivka, Robert
- Subjects
PROPORTIONAL hazards models ,NATURAL history ,IDIOPATHIC pulmonary fibrosis - Abstract
Background: Several registries of idiopathic pulmonary fibrosis (IPF) have been established to better understand its natural history, though their size and duration of follow-up are limited. Here, we describe the large European MultiPartner IPF Registry (EMPIRE) and validate predictors of long-term survival in IPF.Methods: The multinational prospective EMPIRE registry enrolled IPF patients from 48 sites in 10 Central and Eastern European countries since 2014. Survival from IPF diagnosis until death was estimated, accounting for left-truncation. The Cox proportional hazards regression model was used to estimate adjusted hazard ratios (HR) of death for prognostic factors, using restricted cubic splines to fit continuous factors.Results: The cohort included 1620 patients (mean age at diagnosis 67.6 years, 71% male, 63% smoking history), including 75% enrolled within 6 months of diagnosis. Median survival was 4.5 years, with 45% surviving 5 years post-diagnosis. Compared with GAP stage I, mortality was higher with GAP stages II (HR 2.9; 95% CI: 2.3-3.7) and III (HR 4.0; 95% CI: 2.8-5.7) while, with redefined cut-offs, the corresponding HRs were 2.7 (95% CI: 1.8-4.0) and 5.8 (95% CI: 4.0-8.3) respectively. Mortality was higher with concurrent pulmonary hypertension (HR 2.0; 95% CI: 1.5-2.9) and lung cancer (HR 2.6; 95% CI: 1.3-4.9).Conclusions: EMPIRE, one of the largest long-term registries of patients with IPF, provides a more accurate confirmation of prognostic factors and co-morbidities on longer term five-year mortality. It also suggests that some fine-tuning of the indices for mortality may provide a more accurate long-term prognostic profile for these patients. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
6. Altitude and COPD prevalence: analysis of the PREPOCOL-PLATINO-BOLD-EPI-SCAN study
- Author
-
Horner, Andreas; https://orcid.org/0000-0001-7746-3335, Soriano, Joan B, Puhan, Milo A, Studnicka, Michael, Kaiser, Bernhard, Vanfleteren, Lowie E G W, Gnatiuc, Louisa, Burney, Peter, Miravitlles, Marc, García-Rio, Francisco, Ancochea, Julio, Menezes, Ana M, Perez-Padilla, Rogelio, Montes de Oca, Maria, Torres-Duque, Carlos A, Caballero, Andres, González-García, Mauricio, Buist, Sonia, Flamm, Maria, Lamprecht, Bernd, Horner, Andreas; https://orcid.org/0000-0001-7746-3335, Soriano, Joan B, Puhan, Milo A, Studnicka, Michael, Kaiser, Bernhard, Vanfleteren, Lowie E G W, Gnatiuc, Louisa, Burney, Peter, Miravitlles, Marc, García-Rio, Francisco, Ancochea, Julio, Menezes, Ana M, Perez-Padilla, Rogelio, Montes de Oca, Maria, Torres-Duque, Carlos A, Caballero, Andres, González-García, Mauricio, Buist, Sonia, Flamm, Maria, and Lamprecht, Bernd
- Abstract
BACKGROUND: COPD prevalence is highly variable and geographical altitude has been linked to it, yet with conflicting results. We aimed to investigate this association, considering well known risk factors. METHODS: A pooled analysis of individual data from the PREPOCOL-PLATINO-BOLD-EPI-SCAN studies was used to disentangle the population effect of geographical altitude on COPD prevalence. Post-bronchodilator FEV1/FVC below the lower limit of normal defined airflow limitation consistent with COPD. High altitude was defined as >1500 m above sea level. Undiagnosed COPD was considered when participants had airflow limitation but did not report a prior diagnosis of COPD. RESULTS: Among 30,874 participants aged 56.1 ± 11.3 years from 44 sites worldwide, 55.8% were women, 49.6% never-smokers, and 12.9% (3978 subjects) were residing above 1500 m. COPD prevalence was significantly lower in participants living at high altitude with a prevalence of 8.5% compared to 9.9%, respectively (p < 0.005). However, known risk factors were significantly less frequent at high altitude. Hence, in the adjusted multivariate analysis, altitude itself had no significant influence on COPD prevalence. Living at high altitude, however, was associated with a significantly increased risk of undiagnosed COPD. Furthermore, subjects with airflow limitation living at high altitude reported significantly less respiratory symptoms compared to subjects residing at lower altitude. CONCLUSION: Living at high altitude is not associated with a difference in COPD prevalence after accounting for individual risk factors. However, high altitude itself was associated with an increased risk of undiagnosed COPD.
- Published
- 2017
7. Respiratory Research / Neutrophil extracellular trap (NET) formation characterises stable and exacerbated COPD and correlates with airflow limitation
- Author
-
Grabcanovic-Musija, Fikreta, Obermayer, Astrid, Stoiber, Walter, Krautgartner, Wolf-Dietrich, Steinbacher, Peter, Winterberg, Nicole, Bathke, Arne Cornelius, Klappacher, Michaela, and Studnicka, Michael
- Subjects
respiratory tract diseases - Abstract
Background: COPD is a progressive disease of the airways that is characterized by neutrophilic inflammation, a condition known to promote the excessive formation of neutrophil extracellular traps (NETs). The presence of large amounts of NETs has recently been demonstrated for a variety of inflammatory lung diseases including cystic fibrosis, asthma and exacerbated COPD. Objective: We test whether excessive NET generation is restricted to exacerbation of COPD or whether it also occurs during stable periods of the disease, and whether NET presence and amount correlates with the severity of airflow limitation. Patients, materials and methods: Sputum samples from four study groups were examined: COPD patients during acute exacerbation, patients with stable disease, and smoking and non-smoking controls without airflow limitation. Sputum induction followed the ECLIPSE protocol. Confocal laser microscopy (CLSM) and electron microscopy were used to analyse samples. Immunolabelling and fluorescent DNA staining were applied to trace NETs and related marker proteins. CLSM specimens served for quantitative evaluation. Results: Sputum of COPD patients is clearly characterised by NETs and NET-forming neutrophils. The presence of large amounts of NET is associated with disease severity ( p < 0.001): over 90 % in exacerbated COPD, 45 % in stable COPD, and 25 % in smoking controls, but less than 5 % in non-smokers. Quantification of NET-covered areas in sputum preparations confirms these results. Conclusions: NET formation is not confined to exacerbation but also present in stable COPD and correlates with the severity of airflow limitation. We infer that NETs are a major contributor to chronic inflammatory and lung tissue damage in COPD.
- Published
- 2015
8. Altitude and COPD prevalence: analysis of the PREPOCOL-PLATINO-BOLD-EPI-SCAN study.
- Author
-
Horner, Andreas, Soriano, Joan B., Puhan, Milo A., Studnicka, Michael, Kaiser, Bernhard, Vanfleteren, Lowie E. G. W., Gnatiuc, Louisa, Burney, Peter, Miravitlles, Marc, García-Rio, Francisco, Ancochea, Julio, Menezes, Ana M., Perez-Padilla, Rogelio, de Oca, Maria Montes, Torres-Duque, Carlos A., Caballero, Andres, González-García, Mauricio, Buist, Sonia, Flamm, Maria, and Lamprecht, Bernd
- Subjects
OBSTRUCTIVE lung diseases ,BRONCHODILATOR agents ,AIR pollution ,SYMPTOMS ,RESPIRATORY disease diagnosis ,OBSTRUCTIVE lung disease diagnosis ,ALTITUDES ,STATISTICAL sampling ,SPIROMETRY ,DISEASE prevalence ,VITAL capacity (Respiration) - Abstract
Background: COPD prevalence is highly variable and geographical altitude has been linked to it, yet with conflicting results. We aimed to investigate this association, considering well known risk factors.Methods: A pooled analysis of individual data from the PREPOCOL-PLATINO-BOLD-EPI-SCAN studies was used to disentangle the population effect of geographical altitude on COPD prevalence. Post-bronchodilator FEV1/FVC below the lower limit of normal defined airflow limitation consistent with COPD. High altitude was defined as >1500 m above sea level. Undiagnosed COPD was considered when participants had airflow limitation but did not report a prior diagnosis of COPD.Results: Among 30,874 participants aged 56.1 ± 11.3 years from 44 sites worldwide, 55.8% were women, 49.6% never-smokers, and 12.9% (3978 subjects) were residing above 1500 m. COPD prevalence was significantly lower in participants living at high altitude with a prevalence of 8.5% compared to 9.9%, respectively (p < 0.005). However, known risk factors were significantly less frequent at high altitude. Hence, in the adjusted multivariate analysis, altitude itself had no significant influence on COPD prevalence. Living at high altitude, however, was associated with a significantly increased risk of undiagnosed COPD. Furthermore, subjects with airflow limitation living at high altitude reported significantly less respiratory symptoms compared to subjects residing at lower altitude.Conclusion: Living at high altitude is not associated with a difference in COPD prevalence after accounting for individual risk factors. However, high altitude itself was associated with an increased risk of undiagnosed COPD. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
9. Normal tissue complication models for clinically relevant acute esophagitis (≥ grade 2) in patients treated with dose differentiated accelerated radiotherapy (DART-bid).
- Author
-
Zehentmayr, Franz, Söhn, Matthias, Exeli, Ann-Katrin, Wurstbauer, Karl, Tröller, Almut, Deutschmann, Heinz, Fastner, Gerd, Fussl, Christoph, Steininger, Philipp, Kranzinger, Manfred, Belka, Claus, Studnicka, Michael, and Sedlmayer, Felix
- Subjects
NON-small-cell lung carcinoma ,CANCER chemotherapy ,CANCER treatment ,LOGISTIC regression analysis ,TOXICITY testing - Abstract
Background: One of the primary dose-limiting toxicities during thoracic irradiation is acute esophagitis (AE). The aim of this study is to investigate dosimetric and clinical predictors for AE grade ≥ 2 in patients treated with accelerated radiotherapy for locally advanced non-small cell lung cancer (NSCLC). Patients and methods: 66 NSCLC patients were included in the present analysis: 4 stage II, 44 stage IIIA and 18 stage IIIB. All patients received induction chemotherapy followed by dose differentiated accelerated radiotherapy (DART-bid). Depending on size (mean of three perpendicular diameters) tumors were binned in four dose groups: <2.5 cm 73.8 Gy, 2.5-4.5 cm 79.2 Gy, 4.5-6 cm 84.6 Gy, >6 cm 90 Gy. Patients were treated in 3D target splitting technique. In order to estimate the normal tissue complication probability (NTCP), two Lyman models and the cutoff-logistic regression model were fitted to the data with AE ≥ grade 2 as statistical endpoint. Inter-model comparison was performed with the corrected Akaike information criterion (AIC
c ), which calculates the model's quality of fit (likelihood value) in relation to its complexity (i.e. number of variables in the model) corrected by the number of patients in the dataset. Toxicity was documented prospectively according to RTOG. Results: The median follow up was 686 days (range 84-2921 days), 23/66 patients (35 %) experienced AE ≥ grade 2. The actuarial local control rates were 72.6 % and 59.4 % at 2 and 3 years, regional control was 91 % at both time points. The Lyman-MED model (D50 = 32.8 Gy, m = 0.48) and the cutoff dose model (Dc =38 Gy) provide the most efficient fit to the current dataset. On multivariate analysis V38 (volume of the esophagus that receives 38 Gy or above, 95 %-CI 28.2-57.3) was the most significant predictor of AE ≥ grade 2 (HR = 1.05, CI 1.01-1.09, p = 0.007). Conclusion: Following high-dose accelerated radiotherapy the rate of AE ≥ grade 2 is slightly lower than reported for concomitant radio-chemotherapy with the additional benefit of markedly increased loco-regional tumor control. In the current patient cohort the most significant predictor of AE was found to be V38. A second clinically useful parameter in treatment planning may be MED (mean esophageal dose). [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
10. Neutrophil extracellular trap (NET) formation characterises stable and exacerbated COPD and correlates with airflow limitation.
- Author
-
Grabcanovic-Musija, Fikreta, Obermayer, Astrid, Stoiber, Walter, Krautgartner, Wolf-Dietrich, Steinbacher, Peter, Winterberg, Nicole, Bathke, Arne Cornelius, Klappacher, Michaela, and Studnicka, Michael
- Subjects
NEUTROPHILS ,OBSTRUCTIVE lung diseases ,AIRWAY (Anatomy) ,LUNG diseases ,CYSTIC fibrosis ,ASTHMA ,DISEASES - Abstract
Background: COPD is a progressive disease of the airways that is characterized by neutrophilic inflammation, a condition known to promote the excessive formation of neutrophil extracellular traps (NETs). The presence of large amounts of NETs has recently been demonstrated for a variety of inflammatory lung diseases including cystic fibrosis, asthma and exacerbated COPD. Objective: We test whether excessive NET generation is restricted to exacerbation of COPD or whether it also occurs during stable periods of the disease, and whether NET presence and amount correlates with the severity of airflow limitation. Patients, materials and methods: Sputum samples from four study groups were examined: COPD patients during acute exacerbation, patients with stable disease, and smoking and non-smoking controls without airflow limitation. Sputum induction followed the ECLIPSE protocol. Confocal laser microscopy (CLSM) and electron microscopy were used to analyse samples. Immunolabelling and fluorescent DNA staining were applied to trace NETs and related marker proteins. CLSM specimens served for quantitative evaluation. Results: Sputum of COPD patients is clearly characterised by NETs and NET-forming neutrophils. The presence of large amounts of NET is associated with disease severity (p < 0.001): over 90% in exacerbated COPD, 45% in stable COPD, and 25% in smoking controls, but less than 5% in non-smokers. Quantification of NET-covered areas in sputum preparations confirms these results. Conclusions: NET formation is not confined to exacerbation but also present in stable COPD and correlates with the severity of airflow limitation. We infer that NETs are a major contributor to chronic inflammatory and lung tissue damage in COPD. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
11. DART-bid (Dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily)-a novel approach for non-resected NSCLC: final results of a prospective study, correlating radiation dose to tumor volume.
- Author
-
Wurstbauer, Karl, Deutschmann, Heinz, Dagn, Karin, Kopp, Peter, Zehentmayr, Franz, Lamprecht, Bernd, Porsch, Peter, Wegleitner, Birgit, Studnicka, Michael, and Sedlmayer, Felix
- Subjects
CANCER radiotherapy ,RADIATION doses ,CANCER chemotherapy ,LUNG cancer treatment ,CANCER relapse ,PULMONARY fibrosis ,LONGITUDINAL method ,FOLLOW-up studies (Medicine) - Abstract
Background: Sequential chemo-radiotherapies with intensive radiation components deliver promising results in non-resected non-small cell lung cancer (NSCLC). In general, radiation doses are determined by dose constraints for normal tissues, not by features relevant for tumor control. DART-bid targets directly the doses required for tumor control, correlating doses to tumor volume in a differentiated mode. Materials/Methods: Radiation doses to primary tumors were aligned along increasing tumor size within 4 groups (<2.5 cm/2.5-4.5 cm/4.5-6.0 cm/>6.0 cm; mean number of three perpendicular diameters). ICRU-doses of 73.8 Gy/ 79.2 Gy/84.6 Gy/90.0 Gy, respectively, were applied. Macroscopically involved nodes were treated with a median dose of 59.4 Gy, nodal sites about 6 cm cranial to involved nodes electively with 45 Gy. Fractional doses were 1.8 Gy twice daily (bid). 2 cycles chemotherapy were given before radiotherapy. Between 2004 and 2009, 160 not selected patients with 164 histologically/cytologically proven NSCLC were enrolled; Stage I: 38 patients; II: 6 pts.; IIIA: 69 pts.; IIIB: 47 pts. Weight loss >5%/3 months: 38 patients (24%). Primary endpoints are local and regional tumor control rates at 2 years (as >90% of locoregional failures occur within 2 years). Secondary endpoints are survival and toxicity. With a minimum follow-up time of 2 years for patients alive, the final results are presented. Results: 32 local and 10 regional recurrences occurred. The local and regional tumor control rates at 2 years are 77% and 93%, respectively. The median overall survival (OS) time is 28.0 months, the 2- and 5-year OS rates are 57% and 19%, respectively. For stage III patients, median OS amounts to 24.3 months, 2- /5-year OS rates to 51% and 18%, respectively. 2 treatment-related deaths (progressive pulmonary fibrosis) occurred in patients with pre-existing pulmonary fibrosis. Further acute and late toxicity was mild. Conclusions: This novel approach yields a high level of locoregional tumor control and survival times. In general it is well tolerated. In all outcome parameters it seems to compare favourably with simultaneous chemoradiotherapies, at present considered 'state of the art'; and is additionally amenable for an unselected patient population. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
12. Health-related quality of life associates with change in FEV 1 in COPD: results from the COSYCONET cohort.
- Author
-
Lutter JI, Jörres RA, Kahnert K, Schwarzkopf L, Studnicka M, Karrasch S, Schulz H, Vogelmeier CF, and Holle R
- Subjects
- Aged, Female, Humans, Linear Models, Male, Middle Aged, Prospective Studies, Severity of Illness Index, Surveys and Questionnaires, Forced Expiratory Volume, Pulmonary Disease, Chronic Obstructive physiopathology, Pulmonary Disease, Chronic Obstructive psychology, Quality of Life
- Abstract
Background: Forced expiratory volume in one second (FEV
1 ) characterizes the pathophysiology of COPD and different trajectories of FEV1 decline have been observed in patients with COPD (e.g. gradual or episodic). There is limited information about the development of patient-reported health-related quality of life (HRQL) over the full range of the natural history of COPD. We examined the longitudinal association between change in FEV1 and change in disease-specific and generic HRQL., Methods: We analysed data of 1734 patients with COPD participating in the COSYCONET cohort with up to 3 years of follow-up. Patients completed the Saint George's Respiratory Questionnaire (SGRQ) and the EQ-5D Visual Analog Scale (EQ VAS). Change score models were used to investigate the relationship between HRQL and FEV1 and to calculate mean changes in HRQL per FEV1 change categories [decrease (≤ - 100 ml), no change, increase (≥ 100 ml)] after 3 years. Applying hierarchical linear models (HLM), we estimated the cross-sectional between-subject difference and the longitudinal within-subject change of HRQL as related to a FEV1 difference or change., Results: We observed a statistically significant deterioration in SGRQ (total score + 1.3 units) after 3 years, which was completely driven by the activity component (+ 4 units). No significant change was found for the generic EQ VAS. Over the same period, 58% of patients experienced a decrease in FEV1 , 28% were recorded as no change in FEV1 , and 13% experienced an increase. The relationship between HRQL and FEV1 was found to be approximately linear with decrease in FEV1 being statistically significantly associated with a deterioration in SGRQ (+ 3.20 units). Increase in FEV1 was associated with improvements in SGRQ (- 3.81 units). The associations between change in FEV1 and the EQ VAS were similar. Results of the HLMs were consistent and highly statistically significant, indicating cross-sectional and longitudinal associations. The largest estimates were found for the association between FEV1 and the SGRQ activity domain., Conclusions: Difference and change in FEV1 over time correlate with difference and change in disease-specific and generic HRQL. We conclude, that deterioration of HRQL should induce timely re-examination of physical status and lung function and possibly reassessment of therapeutic regimes., Trial Registration: NCT01245933. Date of registration: 18 November 2010.- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.